Optimizing Patient Outcomes in Diabetic Retinopathy

Ophthalmology
Curriculum:
Optimizing Patient Outcomes in Diabetic Retinopathy
Credits:
1.00 AMA PRA Category 1 Credit(s)
Launch Date:
January 21, 2020
Expiration Date:
January 21, 2021

Primary Audience:

Ophthalmologists

Relevant Terms:

Diabetic Retinopathy

Charles C Wykoff, MD, PhD

Charles C Wykoff, MD, PhD
Director of Research, Retina Consultants of Houston
Deputy Chair for Ophthalmology, Blanton Eye Institute
Associate Clinical Professor of Ophthalmology, Weill Cornell Medical College Houston Methodist Hospital
Houston Texas

Charles C. Wykoff MD PhD is Director of Research, Retina Consultants of Houston; Deputy Chair for Ophthalmology, Blanton Eye Institute and Associate Clinical Professor of Ophthalmology, Weill Cornell Medical College, Houston Methodist Hospital, Houston Texas.

He received his baccalaureate from MIT, PhD from Oxford University while on a Marshall Scholarship, and MD from Harvard Medical School. He completed ophthalmology residency and vitreoretinal fellowship at Bascom Palmer Eye Institute where he served as Chief Resident/Co-Director of Ocular Trauma and received a Heed Fellowship and the Ronald G. Michels Award.

Dr. Wykoff is passionate about translational research and clinical trial design, and has published over 130 peer reviewed manuscripts.  His research interests pertain to angiogenesis and retinal vascular diseases as well as vitreoretinal surgical topics. He has been awarded the AAO Secretariat and Achievement Awards as well as the ASRS Honor and Senior Honor Awards.  He is an elected member of The Retina Society and The Macula Society, was a founding member of the Ophthalmology Retina Editorial Board, and serves as the Academic Program Director for the Vit-Buckle Society.  

Dr Wykoff is actively involved in entrepreneurial activities and serves on multiple scientific advisory boards and global clinical-trial steering committees for companies spanning the innovative process from early to late stage development.  His guiding philosophy is to build and strengthen innovative, ethical teams focused on developing new approaches to improving outcomes for blinding diseases.

Eric W Schneider, MD

Eric W Schneider, MD
Tennessee Retina, Partner and Vitreoretinal Surgeon
Nashville Tennessee

Eric Schneider, MD is a retina specialist and partner at Tennessee Retina PC in Nashville, Tennessee.  He completed his medical school and ophthalmology residency at the University of Michigan Medical School and completed his fellowship in vitreoretinal surgery at Duke University. 

He is a member of numerous professional societies including the American Society of Retina Specialists (ASRS), the Association for Research in Vision and Ophthalmology, Club Vit, and the American Academy of Ophthalmology. 

He serves as a member of the ASRS Research and Safety in Therapeutics committee and the Medicare-Based Incentive Program measure development task force, in addition to serving as the representative to the Medicare Contractor Advisory Committee for ophthalmology in the state of Tennessee. 

He has authored or co-authored over 20 peer reviewed articles and served as an investigator in numerous clinical trials.  His research focuses on treatment of refractory age-related macular degeneration, diabetic retinopathy, vitreoretinal interface disease, and novel OCT applications including OCT angiography

William W Li, MD

William W Li, MD
President and Chief Executive Officer, The Angiogenesis Foundation
Cambridge, MA

Dr. William W. Li is President, Medical Director, and co-founder of the Angiogenesis Foundation, a nonprofit scientific organization that is re-conceptualizing global disease fighting.  Since 1993, Dr. Li has been leading international efforts to develop effective therapeutic strategies based on angiogenesis including ophthalmology, oncology, wound care and regenerative medicine, and to improve treatment using these modalities by health systems and clinicians using these modalities in safe, effective, and efficient ways, through evidence-based practice. A major part of Dr. Li’s work focuses on identifying gaps and opportunities in the clinical application of anti-VEGF therapies for retinal vascular disease, and he has been leading efforts with eye professionals and advocacy groups across North America, Europe, Latin America, and Asia to help prevent vision loss.
1. Identify and compare current treatment pathways for diabetic retinopathy patients and diabetic macular edema and their impact on patient outcomes.
2. Develop consensus on factors responsible for differences in referral pathways for diabetic retinopathy patients and conceptualize patient referral guidelines.
3. Synthesize key outstanding questions regarding timing of patient referral from optometrist to ophthalmologist in diabetic retinopathy.
4. Present recommendations for actions to improve diabetic retinopathy patient referrals to achieve optimal patient outcomes.

LAUNCH DATE/EXPIRATION DATE

This activity was launched on January 20, 2020 and will expire on January 19, 2021.

 

TARGET AUDIENCE
Content and educational strategies have been designed to facilitate behavior change in ophthalmologists, primary care physicians, residents and fellows, physician assistants, nurse practitioners, optomistrists, and all health care providers (HCPs) who care for patients at risk for diabetes and associated retinal disease.

 

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedicusCME and the Angiogenesis Foundation.  MedicusCME is accredited by the ACCME to provide continuing medical education for physicians.

 

DESIGNATION STATEMENT

MedicusCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

MedicusCME’s POLICY ON CONFLICT OF INTEREST

It is the policy of MedicusCME to identify and resolve any potential conflicts of interest of anyyone who may be in a position to influence or control the content of an education activity, to assure balance, independence, objectivity and scientific rigor in all of its accredited activities. All faculty and planners are expected to disclose all financial relationships with a commercial interest within the past twelve months.

 

CONFLICT OF INTEREST DISCLOSURES

Dr. Wykoff acknowledges receipt of consulting fees from Acuela, Alimera Sciences, Allegro, Bayer, DORC, EyePoint, Fosun, ONL Therapeutics, Opthea, Optos, Outlook Therapeutics, Oxurion and PolyPhotonix Takeda for his participation on their respective scientific advisory boards.  He acknowledges receipt of research support from Aerie Pharmaceuticals, Aldeyra Therapeutics, Gemini Therapeutics, Graybug Vision, IONIS Pharmaceuticals, Neurotech, Opthea, Outlook Therapeutics, Samsung, Senju Pharmaceuticals and Xbrane Biopharma; and of both consulting fees and research support from Adverum, Aerpio, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Genentech/Roche, Iveric Bio (formerly Ophthotech), Kodiak, Novartis, Optos, Recens Medical, Regenxbio, Regeneron and Santen. Additionally, he owns stock in Regeneron.

All other planners, faculty, authors and presenters of this accredited activity deny any personal or financial relationships with ACCME-defined commercial entities that may constitute any real or perceived conflict of interest.

 

HOW TO CLAIM CREDIT

By participating in all course content and learning strategies, and successfully completing the

post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™.
 

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

 

COURSE FORMAT/MEDIUM: Internet Activity (Enduring Material)

 

ESTIMATED TIME TO COMPLETE: 60 minutes

 

ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals.

 

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

 

FACULTY

William W. Li, MD

President and Chief Executive Officer, The Angiogenesis Foundation

 

Eric W Schneider, MD

Tennessee Retina, Partner and Vitreoretinal Surgeon

Nashville Tennessee

 

Charles C. Wykoff, MD, PhD, FACS

Clinical Associate Professor of Ophthalmology, Weill Cornell Medical College

Physician, Surgeon, Director of Research, Retinal Consultants of Houston, PA Director of Clinical

Research and Vice-President, Greater Houston Retina Research Foundation

Houston, Texas

 

Brad H. Feldman, MD

Ophthalmologist and Surgeon, Wills Eye Hospital

Clinical Instructor in Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University

Philadelphia, Pennsylvania

 

Steven Haimowitz, MD

President, RealCME

 

Carol Pashman, MS, RN

President, MedicusCME

 

Jeff McRae, MS

Grants Administrator, The Angiogenesis Foundation

 

COURSE VIEWING REQUIREMENTS

Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above